A phase II study published in Frontiers in Oncology last month investigated the potential of a new targeted therapy called anlotinib for the treatment of people with metastatic renal cell carcinoma (RCC) that had already been treated with a VEGF tyrosine kinase inhibitor (TKI).

Forty-two (42) patients were included in the study. The cancer progressed in 32 patients who had previously taken sorafenib or sunitinib, and 10 patients did not tolerate the treatment. After treatment with anlotinib, median progression-free survival was 14.0 months for the overall population and 8.5 months for the patients whose cancer had progressed after a previous sorafenib or sunitinib. In the overall population, median overall survival was 21.4 months, objective response rate was 16.7%, and the disease control rate was 83.3%. Frequently reported adverse events included diarrhoea, hypertension, hand–foot syndrome, and fatigue.

In conclusion, this study shows that anlotinib has potential and a second-line treatment for patients with metastatic RCC. However, further studies are needed, particularly in combination with immunotherapy.

Read more in Frontiers in Oncology here